Does the media refer more to AVR or OBIO?

In the previous week, Orchestra BioMed had 1 more articles in the media than Anteris Technologies Global. MarketBeat recorded 4 mentions for Orchestra BioMed and 3 mentions for Anteris Technologies Global. Anteris Technologies Global's average media sentiment score of 0.89 beat Orchestra BioMed's score of 0.30 indicating that Anteris Technologies Global is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anteris Technologies Global 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, OBIO or INMD?

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Orchestra BioMed $33.48M 6.63 -$52.70M -$0.97 N/A InMode $370.49M 2.40 $93.83M $1.36 11.39

Is OBIO or INMD more profitable?

InMode has a net margin of 23.27% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 13.47% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% InMode 23.27% 13.47% 11.95%

Does the media favor OBIO or INMD?

In the previous week, InMode had 4 more articles in the media than Orchestra BioMed. MarketBeat recorded 8 mentions for InMode and 4 mentions for Orchestra BioMed. InMode's average media sentiment score of 0.32 beat Orchestra BioMed's score of 0.30 indicating that InMode is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InMode 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SIBN or OBIO more profitable?

SiBone has a net margin of -8.10% compared to Orchestra BioMed's net margin of -166.96%. SiBone's return on equity of -9.56% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Orchestra BioMed -166.96% -157.46% -60.18%

Does the media favor SIBN or OBIO?

In the previous week, SiBone had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 5 mentions for SiBone and 4 mentions for Orchestra BioMed. SiBone's average media sentiment score of 0.58 beat Orchestra BioMed's score of 0.30 indicating that SiBone is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BBNX or OBIO?

In the previous week, Orchestra BioMed had 2 more articles in the media than Beta Bionics. MarketBeat recorded 4 mentions for Orchestra BioMed and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat Orchestra BioMed's score of 0.30 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Orchestra BioMed 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OBIO or CBLL more profitable?

CeriBell has a net margin of -63.51% compared to Orchestra BioMed's net margin of -166.96%. CeriBell's return on equity of -38.19% beat Orchestra BioMed's return on equity. Company Net Margins Return on Equity Return on Assets Orchestra BioMed -166.96% -157.46% -60.18% CeriBell -63.51% -38.19% -30.92%

Orchestra BioMed (OBIO) Competitors

$3.72 -0.01 (-0.13%)

As of 10:36 AM Eastern

Compare

OBIO vs. AVR, INMD, SIBN, BBNX, and CBLL

Should you buy Orchestra BioMed stock or one of its competitors? MarketBeat compares Orchestra BioMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orchestra BioMed include Anteris Technologies Global (AVR), InMode (INMD), SiBone (SIBN), Beta Bionics (BBNX), and CeriBell (CBLL). These companies are all part of the "medical equipment" industry.

How does Orchestra BioMed compare to Anteris Technologies Global?

Anteris Technologies Global (NASDAQ:AVR) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Orchestra BioMed has higher revenue and earnings than Anteris Technologies Global. Orchestra BioMed is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anteris Technologies Global	$1.91M	432.63	-$94.14M	-$2.23	N/A
Orchestra BioMed	$33.48M	6.63	-$52.70M	-$0.97	N/A

Anteris Technologies Global has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

53.2% of Orchestra BioMed shares are owned by institutional investors. 4.5% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Anteris Technologies Global currently has a consensus price target of $16.00, suggesting a potential upside of 88.48%. Orchestra BioMed has a consensus price target of $13.60, suggesting a potential upside of 267.07%. Given Orchestra BioMed's higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Anteris Technologies Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Orchestra BioMed had 1 more articles in the media than Anteris Technologies Global. MarketBeat recorded 4 mentions for Orchestra BioMed and 3 mentions for Anteris Technologies Global. Anteris Technologies Global's average media sentiment score of 0.89 beat Orchestra BioMed's score of 0.30 indicating that Anteris Technologies Global is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anteris Technologies Global	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Orchestra BioMed has a net margin of -166.96% compared to Anteris Technologies Global's net margin of -5,148.78%. Anteris Technologies Global's return on equity of -124.76% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

Summary

Orchestra BioMed beats Anteris Technologies Global on 10 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to InMode?

Orchestra BioMed (NASDAQ:OBIO) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 68.0% of InMode shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Comparatively, 6.9% of InMode shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Orchestra BioMed presently has a consensus price target of $13.60, indicating a potential upside of 267.07%. InMode has a consensus price target of $16.00, indicating a potential upside of 3.26%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InMode has a net margin of 23.27% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 13.47% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
InMode	23.27%	13.47%	11.95%

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	6.63	-$52.70M	-$0.97	N/A
InMode	$370.49M	2.40	$93.83M	$1.36	11.39

Orchestra BioMed has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, InMode has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

In the previous week, InMode had 4 more articles in the media than Orchestra BioMed. MarketBeat recorded 8 mentions for InMode and 4 mentions for Orchestra BioMed. InMode's average media sentiment score of 0.32 beat Orchestra BioMed's score of 0.30 indicating that InMode is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMode	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InMode beats Orchestra BioMed on 11 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to SiBone?

SiBone (NASDAQ:SIBN) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

98.1% of SiBone shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

SiBone has a net margin of -8.10% compared to Orchestra BioMed's net margin of -166.96%. SiBone's return on equity of -9.56% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

SiBone presently has a consensus price target of $23.50, indicating a potential upside of 34.86%. Orchestra BioMed has a consensus price target of $13.60, indicating a potential upside of 267.07%. Given Orchestra BioMed's higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, SiBone had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 5 mentions for SiBone and 4 mentions for Orchestra BioMed. SiBone's average media sentiment score of 0.58 beat Orchestra BioMed's score of 0.30 indicating that SiBone is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

SiBone has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

SiBone has higher revenue and earnings than Orchestra BioMed. SiBone is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.85	-$18.90M	-$0.39	N/A
Orchestra BioMed	$33.48M	6.63	-$52.70M	-$0.97	N/A

Summary

SiBone beats Orchestra BioMed on 12 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Orchestra BioMed has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	7.51	-$73.20M	-$1.51	N/A
Orchestra BioMed	$33.48M	6.63	-$52.70M	-$0.97	N/A

Beta Bionics has a beta of 3.04, indicating that its share price is 204% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

In the previous week, Orchestra BioMed had 2 more articles in the media than Beta Bionics. MarketBeat recorded 4 mentions for Orchestra BioMed and 2 mentions for Beta Bionics. Beta Bionics' average media sentiment score of 1.08 beat Orchestra BioMed's score of 0.30 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beta Bionics currently has a consensus target price of $20.30, indicating a potential upside of 20.23%. Orchestra BioMed has a consensus target price of $13.60, indicating a potential upside of 267.07%. Given Orchestra BioMed's higher probable upside, analysts plainly believe Orchestra BioMed is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Beta Bionics has a net margin of -60.27% compared to Orchestra BioMed's net margin of -166.96%. Beta Bionics' return on equity of -23.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

53.2% of Orchestra BioMed shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Beta Bionics beats Orchestra BioMed on 10 of the 17 factors compared between the two stocks.

How does Orchestra BioMed compare to CeriBell?

Orchestra BioMed (NASDAQ:OBIO) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Orchestra BioMed has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orchestra BioMed	$33.48M	6.63	-$52.70M	-$0.97	N/A
CeriBell	$89.06M	8.03	-$53.41M	-$1.63	N/A

CeriBell has a net margin of -63.51% compared to Orchestra BioMed's net margin of -166.96%. CeriBell's return on equity of -38.19% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-166.96%	-157.46%	-60.18%
CeriBell	-63.51%	-38.19%	-30.92%

Orchestra BioMed currently has a consensus price target of $13.60, suggesting a potential upside of 267.07%. CeriBell has a consensus price target of $22.20, suggesting a potential upside of 17.82%. Given Orchestra BioMed's higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by company insiders. Comparatively, 20.1% of CeriBell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Orchestra BioMed has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

In the previous week, Orchestra BioMed had 3 more articles in the media than CeriBell. MarketBeat recorded 4 mentions for Orchestra BioMed and 1 mentions for CeriBell. CeriBell's average media sentiment score of 0.72 beat Orchestra BioMed's score of 0.30 indicating that CeriBell is being referred to more favorably in the news media.

Company	Overall Sentiment
Orchestra BioMed	Neutral
CeriBell	Positive

Summary

CeriBell beats Orchestra BioMed on 10 of the 17 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBIO vs. The Competition

Export

Metric	Orchestra BioMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$221.86M	$3.72B	$6.91B	$12.20B
Dividend Yield	N/A	2.20%	2.68%	8.87%
P/E Ratio	-3.82	21.46	27.23	23.90
Price / Sales	6.63	301.02	573.53	111.21
Price / Cash	N/A	146.26	49.25	59.89
Price / Book	3.90	8.40	10.85	6.19
Net Income	-$52.70M	$23.83M	$3.59B	$331.84M
7 Day Performance	-6.89%	-4.01%	-2.26%	-2.30%
1 Month Performance	-4.01%	2.73%	1.89%	-1.63%
1 Year Performance	17.19%	43.29%	23.86%	16.11%

Orchestra BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBIO Orchestra BioMed	4.3633 of 5 stars	$3.71 -0.4%	$13.60 +267.1%	+18.1%	$221.86M	$33.48M	N/A	4	News Coverage Short Interest Increase
AVR Anteris Technologies Global	2.9277 of 5 stars	$8.92 -0.3%	$16.00 +79.3%	+181.8%	$873.14M	$1.91M	N/A	138
INMD InMode	1.7323 of 5 stars	$15.10 +1.2%	$16.00 +6.0%	+9.4%	$867.60M	$370.49M	11.10	480	News Coverage Upcoming Earnings Gap Down
SIBN SiBone	2.7244 of 5 stars	$17.13 +1.3%	$23.00 +34.3%	+3.6%	$759.18M	$200.93M	N/A	350	Analyst Forecast
BBNX Beta Bionics	2.318 of 5 stars	$16.91 +0.3%	$20.30 +20.0%	+33.5%	$753.06M	$100.25M	N/A	294	Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBIO) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orchestra BioMed (OBIO) Competitors

OBIO vs. AVR, INMD, SIBN, BBNX, and CBLL

How does Orchestra BioMed compare to Anteris Technologies Global?

Summary

How does Orchestra BioMed compare to InMode?

Summary

How does Orchestra BioMed compare to SiBone?

Summary

How does Orchestra BioMed compare to Beta Bionics?

Summary

How does Orchestra BioMed compare to CeriBell?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orchestra BioMed (OBIO) Competitors

OBIO vs. AVR, INMD, SIBN, BBNX, and CBLL

How does Orchestra BioMed compare to Anteris Technologies Global?

Which has higher valuation and earnings, AVR or OBIO?

Which has more volatility & risk, AVR or OBIO?

Do institutionals and insiders have more ownership in AVR or OBIO?

Do analysts prefer AVR or OBIO?

Does the media refer more to AVR or OBIO?

Is AVR or OBIO more profitable?

Summary

How does Orchestra BioMed compare to InMode?

Do institutionals and insiders hold more shares of OBIO or INMD?

Do analysts recommend OBIO or INMD?

Is OBIO or INMD more profitable?

Which has higher valuation and earnings, OBIO or INMD?

Which has more risk and volatility, OBIO or INMD?

Does the media favor OBIO or INMD?

Summary

How does Orchestra BioMed compare to SiBone?

Do insiders and institutionals have more ownership in SIBN or OBIO?

Is SIBN or OBIO more profitable?

Do analysts rate SIBN or OBIO?

Does the media favor SIBN or OBIO?

Which has more risk & volatility, SIBN or OBIO?

Which has higher valuation and earnings, SIBN or OBIO?

Summary

How does Orchestra BioMed compare to Beta Bionics?

Which has better valuation & earnings, BBNX or OBIO?

Which has more risk and volatility, BBNX or OBIO?

Does the media favor BBNX or OBIO?

Do analysts recommend BBNX or OBIO?

Is BBNX or OBIO more profitable?

Do insiders & institutionals have more ownership in BBNX or OBIO?

Summary

How does Orchestra BioMed compare to CeriBell?

Which has preferable earnings & valuation, OBIO or CBLL?

Is OBIO or CBLL more profitable?

Do analysts recommend OBIO or CBLL?

Do institutionals & insiders hold more shares of OBIO or CBLL?

Which has more volatility & risk, OBIO or CBLL?

Does the media favor OBIO or CBLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools